Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (27447)	1/18/1999 6:22:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Atually, SBH's Avandia is a few months ahead of LLY's Actos. I think that both are considered second generation TZDs. I believe that Avandia is used a concentrations which are about 2 logs lower than Rezulin and I would assume that Actos is also effective at a lower concentration. I have read more on Avandia, which in trials did not produce liver damage as measure by liver function tests. I suspect that both drugs will get priority review and will put a good deal of pressure on Rezulin. Details are linked to Ligand's Diabetes page at biocognizance.com